Impact of immunopathology on the antituberculous activity of pyrazinamide

Landry Blanc, Jansy Passiflora Sarathy, Nadine Alvarez Cabrera, Paul O’Brien, Isabela Dias‑Freedman, Marizel Mina, James Sacchettini, Radojka M. Savic, Martin Gengenbacher, Brendan K. Podell, Brendan Prideaux, Thomas Ioerger, Thomas Dick, Véronique Dartois

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

In the 1970s, inclusion of pyrazinamide (PZA) in the drug regimen of tuberculosis (TB) patients for the first 2 mo achieved a drastic reduction of therapy duration. Until now, however, the mechanisms underlying PZA’s unique contribution to efficacy have remained controversial, and animal efficacy data vary across species. To understand how PZA kills bacterial populations present in critical lung lesion compartments, we first characterized a rabbit model of active TB, showing striking similarities in lesion types and fates to nonhuman primate models deemed the most appropriate surrogates of human TB. We next employed this model with lesion-centric molecular and bacteriology readouts to demonstrate that PZA exhibits potent activity against Mycobacterium tuberculosis residing in difficult-to-sterilize necrotic lesions. Our data also indicate that PZA is slow acting, suggesting that PZA administration beyond the first 2 mo may accelerate the cure. In conclusion, we provide a pharmacodynamic explanation for PZA’s treatment-shortening effect and deliver new tools to dissect the contribution of immune response versus drug at the lesion level.

Original languageEnglish (US)
Pages (from-to)1975-1986
Number of pages12
JournalJournal of Experimental Medicine
Volume215
Issue number8
DOIs
StatePublished - Sep 1 2018
Externally publishedYes

Fingerprint

Pyrazinamide
Tuberculosis
Bacteriology
Mycobacterium tuberculosis
Pharmaceutical Preparations
Primates
Rabbits
Lung
Therapeutics
Population

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Blanc, L., Sarathy, J. P., Cabrera, N. A., O’Brien, P., Dias‑Freedman, I., Mina, M., ... Dartois, V. (2018). Impact of immunopathology on the antituberculous activity of pyrazinamide. Journal of Experimental Medicine, 215(8), 1975-1986. https://doi.org/10.1084/jem.20180518

Impact of immunopathology on the antituberculous activity of pyrazinamide. / Blanc, Landry; Sarathy, Jansy Passiflora; Cabrera, Nadine Alvarez; O’Brien, Paul; Dias‑Freedman, Isabela; Mina, Marizel; Sacchettini, James; Savic, Radojka M.; Gengenbacher, Martin; Podell, Brendan K.; Prideaux, Brendan; Ioerger, Thomas; Dick, Thomas; Dartois, Véronique.

In: Journal of Experimental Medicine, Vol. 215, No. 8, 01.09.2018, p. 1975-1986.

Research output: Contribution to journalArticle

Blanc, L, Sarathy, JP, Cabrera, NA, O’Brien, P, Dias‑Freedman, I, Mina, M, Sacchettini, J, Savic, RM, Gengenbacher, M, Podell, BK, Prideaux, B, Ioerger, T, Dick, T & Dartois, V 2018, 'Impact of immunopathology on the antituberculous activity of pyrazinamide', Journal of Experimental Medicine, vol. 215, no. 8, pp. 1975-1986. https://doi.org/10.1084/jem.20180518
Blanc L, Sarathy JP, Cabrera NA, O’Brien P, Dias‑Freedman I, Mina M et al. Impact of immunopathology on the antituberculous activity of pyrazinamide. Journal of Experimental Medicine. 2018 Sep 1;215(8):1975-1986. https://doi.org/10.1084/jem.20180518
Blanc, Landry ; Sarathy, Jansy Passiflora ; Cabrera, Nadine Alvarez ; O’Brien, Paul ; Dias‑Freedman, Isabela ; Mina, Marizel ; Sacchettini, James ; Savic, Radojka M. ; Gengenbacher, Martin ; Podell, Brendan K. ; Prideaux, Brendan ; Ioerger, Thomas ; Dick, Thomas ; Dartois, Véronique. / Impact of immunopathology on the antituberculous activity of pyrazinamide. In: Journal of Experimental Medicine. 2018 ; Vol. 215, No. 8. pp. 1975-1986.
@article{bf5c2f893416484dab2cd49472de44ff,
title = "Impact of immunopathology on the antituberculous activity of pyrazinamide",
abstract = "In the 1970s, inclusion of pyrazinamide (PZA) in the drug regimen of tuberculosis (TB) patients for the first 2 mo achieved a drastic reduction of therapy duration. Until now, however, the mechanisms underlying PZA’s unique contribution to efficacy have remained controversial, and animal efficacy data vary across species. To understand how PZA kills bacterial populations present in critical lung lesion compartments, we first characterized a rabbit model of active TB, showing striking similarities in lesion types and fates to nonhuman primate models deemed the most appropriate surrogates of human TB. We next employed this model with lesion-centric molecular and bacteriology readouts to demonstrate that PZA exhibits potent activity against Mycobacterium tuberculosis residing in difficult-to-sterilize necrotic lesions. Our data also indicate that PZA is slow acting, suggesting that PZA administration beyond the first 2 mo may accelerate the cure. In conclusion, we provide a pharmacodynamic explanation for PZA’s treatment-shortening effect and deliver new tools to dissect the contribution of immune response versus drug at the lesion level.",
author = "Landry Blanc and Sarathy, {Jansy Passiflora} and Cabrera, {Nadine Alvarez} and Paul O’Brien and Isabela Dias‑Freedman and Marizel Mina and James Sacchettini and Savic, {Radojka M.} and Martin Gengenbacher and Podell, {Brendan K.} and Brendan Prideaux and Thomas Ioerger and Thomas Dick and V{\'e}ronique Dartois",
year = "2018",
month = "9",
day = "1",
doi = "10.1084/jem.20180518",
language = "English (US)",
volume = "215",
pages = "1975--1986",
journal = "Journal of Experimental Medicine",
issn = "0022-1007",
publisher = "Rockefeller University Press",
number = "8",

}

TY - JOUR

T1 - Impact of immunopathology on the antituberculous activity of pyrazinamide

AU - Blanc, Landry

AU - Sarathy, Jansy Passiflora

AU - Cabrera, Nadine Alvarez

AU - O’Brien, Paul

AU - Dias‑Freedman, Isabela

AU - Mina, Marizel

AU - Sacchettini, James

AU - Savic, Radojka M.

AU - Gengenbacher, Martin

AU - Podell, Brendan K.

AU - Prideaux, Brendan

AU - Ioerger, Thomas

AU - Dick, Thomas

AU - Dartois, Véronique

PY - 2018/9/1

Y1 - 2018/9/1

N2 - In the 1970s, inclusion of pyrazinamide (PZA) in the drug regimen of tuberculosis (TB) patients for the first 2 mo achieved a drastic reduction of therapy duration. Until now, however, the mechanisms underlying PZA’s unique contribution to efficacy have remained controversial, and animal efficacy data vary across species. To understand how PZA kills bacterial populations present in critical lung lesion compartments, we first characterized a rabbit model of active TB, showing striking similarities in lesion types and fates to nonhuman primate models deemed the most appropriate surrogates of human TB. We next employed this model with lesion-centric molecular and bacteriology readouts to demonstrate that PZA exhibits potent activity against Mycobacterium tuberculosis residing in difficult-to-sterilize necrotic lesions. Our data also indicate that PZA is slow acting, suggesting that PZA administration beyond the first 2 mo may accelerate the cure. In conclusion, we provide a pharmacodynamic explanation for PZA’s treatment-shortening effect and deliver new tools to dissect the contribution of immune response versus drug at the lesion level.

AB - In the 1970s, inclusion of pyrazinamide (PZA) in the drug regimen of tuberculosis (TB) patients for the first 2 mo achieved a drastic reduction of therapy duration. Until now, however, the mechanisms underlying PZA’s unique contribution to efficacy have remained controversial, and animal efficacy data vary across species. To understand how PZA kills bacterial populations present in critical lung lesion compartments, we first characterized a rabbit model of active TB, showing striking similarities in lesion types and fates to nonhuman primate models deemed the most appropriate surrogates of human TB. We next employed this model with lesion-centric molecular and bacteriology readouts to demonstrate that PZA exhibits potent activity against Mycobacterium tuberculosis residing in difficult-to-sterilize necrotic lesions. Our data also indicate that PZA is slow acting, suggesting that PZA administration beyond the first 2 mo may accelerate the cure. In conclusion, we provide a pharmacodynamic explanation for PZA’s treatment-shortening effect and deliver new tools to dissect the contribution of immune response versus drug at the lesion level.

UR - http://www.scopus.com/inward/record.url?scp=85054726707&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054726707&partnerID=8YFLogxK

U2 - 10.1084/jem.20180518

DO - 10.1084/jem.20180518

M3 - Article

C2 - 30018074

AN - SCOPUS:85054726707

VL - 215

SP - 1975

EP - 1986

JO - Journal of Experimental Medicine

JF - Journal of Experimental Medicine

SN - 0022-1007

IS - 8

ER -